Certified by Founder
Lodge
Ability Biologics
start up
Canada
- Montreal, Quebec
- 07/12/2023
- Seed
- $12,000,000
Our Mission:
Develop innovative, targeted, immune modulating biotherapeutics to address unmet medical needs in patients with cancer and autoimmune diseases.
The premier biotherapeutic targeting company
Our powerful AbiLeap™ discovery engine combines massively parallel, continuously learning AI with an extensive database of antigen-antibody interactions to generate fully human, IgG-based multispecific antibodies of exquisite selectivity and affinity. The antibodies respond to environmental signals within the cellular microenvironment, generating logic-gated therapeutics.
We are dedicated to developing the most potent and selective antibody therapeutics for areas of great unmet need.
- Industry Biotechnology Research
- Website https://ability.bio/
- LinkedIn https://www.linkedin.com/company/ability-biologics/about/
Humand | $66,000,000 | (Feb 24, 2026)
Solid (AI for Data) | $20,000,000 | (Feb 24, 2026)
Comeryx | $7,500,000 | (Feb 24, 2026)
Maazah | $2,000,000 | (Feb 24, 2026)
Turgo.ai | $1,000,000 | (Feb 24, 2026)
Sherpas | $3,200,000 | (Feb 24, 2026)
Patientdesk.ai (YC W26) | $1,000,000 | (Feb 24, 2026)
Aalyria | $100,000,000 | (Feb 24, 2026)
Ubicquia, Inc | $106,000,000 | (Feb 24, 2026)